Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

NPF Expands Seal of Recognition to FDA-approved Treatments and Awards its First to Arcutis' ZORYVE® (roflumilast) - Arcutis Biotherapeutics

ALEXANDRIA, VA, UNITED STATES, June 2, 2025 /EINPresswire.com/ —  ● The NPF Seal of Recognition highlights products that prove a commitment to being safe and non-irritating for people with psoriasis or psoriatic arthritis.● NPF has expanded its Seal of Recognition to include FDA approved prescription drugs to better represent the full toolbox of options available for people with psoriatic disease● Recognition underscores ZORYVE’s non-irritating …